Análisis de la acción iSpecimen Inc (ISPC)ISPCiSpecimen Inc

iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting. It operates in the Technology sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

iSpecimen Inc is not a good buy right now. The stock has seen a staggering year-to-date decline of 86.54% and a 1-year change of -94.57%, indicating severe financial distress. Additionally, the current RSI is at 22.911, suggesting the stock is oversold but may not rebound soon. The company's gross margin has fluctuated significantly, with the latest figures showing a gross margin of 45.18% in Q2 2026, but this is overshadowed by consistent net losses, including a net income loss of -1,362,811 USD in Q2 2026. The primary risk is the ongoing financial instability, as indicated by a current ratio of 0.82, which suggests potential liquidity issues. Overall, the combination of poor performance metrics and financial health makes this stock a sell for long-term investors.